

Supplementary Materials

Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease

Xiaodong Dou^{a,#}, Qi Sun^{b,#}, Guofeng Xu^{a,#}, Yameng Liu^a, Caifang Zhang^a, Bingding Wang^a, Yangbin Lu^b, Zheng Guo^b, Lingyu Su^a, Tongyu Huo^a, Xinyi Zhao^a, Chen Wang^a, Zhongtian Yu^b, Song Song^a, Liangren Zhang^a, Zhenming Liu^a, Luhua Lai^{b,c,*}, Ning Jiao^{a,*}

^aState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China

^bBNLMS, Peking-Tsinghua Center for Life Sciences at College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China

^cCenter for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China

These authors contributed equally to this work.

* To whom correspondence should be addressed.

L. Lai: lhlai@pku.edu.cn; N. Jiao: jiaoning@pku.edu.cn

Figure Legends

Figure S1. The concentration-activity relationship for identified SARS-CoV-2 M ^{Pro} inhibitors ...	S2
Figure S2. Predicted binding mode of compound F8-S43	S3
Figure S3. Dose-response curves of the inhibition activity of F8-B6	S4
Figure S4. The inhibition of compounds F8-B6 and F8-B22 against Cathepsin L	S5
Table S1. The chemical structures and enzymatic activities of the 27 analogs of F8	S6
Table S2. Enzymatic activity and chemical structures of the 22 analogs of F8-S43	S9
NMR Spectra	S11




Figure S1. The concentration-activity relationship for identified SARS-CoV-2 M^{pro} inhibitors.




Figure S2. Predicted binding mode of compound **F8-S43**. (A) Superimposition of the crystal structure of SARS-CoV-2 M^{pro} (PDB ID: 7JU7) with compound **F8-S43**. (B) The binding modes of compound **F8-S43** with SARS-CoV-2 M^{pro} in the cartoon. Hydrogen bonds are represented by yellow lines. Images depicting the proposed binding modes were generated using PyMOL software.




Figure S3. Dose-response curves of the inhibition activity of **F8-B6** under different incubation times 5 min (A), 30 min (B), 180 min (C). (D) Dose-response curves of the inhibition activity of **F8-B6** in the presence or absence of DTT.























Figure S4. (A) The inhibition of Cathepsin L inhibitor **FF-FMK**. (B) The concentration-activity relationship for compounds **F8-B6** and **F8-B22** against Cathepsin L. Data are presented as geometric mean values of at least two independent runs.

Table S1. The chemical structures and enzymatic activities of the 27 analogs of **F8**.




Compounds	Core	R ¹	R ²	Inhibition% (50 μM) ^a	IC ₅₀ ± SD (μM) ^a
Tideglusib	—	—	—	98.6	0.30 ± 0.02
F8	A		3-COOH	65.0	21.28 ± 0.89
F8-S44	A		3-COOH, 4-Cl	< 20.0	N.T. ^b
F8-S45	A		3-COOH	28.2	N.T.
F8-S46	A		3-COOH, 4-OH	< 20.0	N.T.
F8-S47	A		3-COOH	34.6	N.T.
F8-S48	A		3-COOH, 4-OH	45.9	N.T.
F8-S49	A		3-NO ₂	< 20.0	N.T.
F8-S50	A		3-COOH, 4-Cl	< 20.0	N.T.
F8-S51	A		4-NO ₂	21.3	N.T.
F8-S52	A		3-COOH	30.0	N.T.









F8-S53	A		2-COOH	< 20.0	N.T.
F8-S54	A		3-COOH	< 20.0	N.T.
F8-S55	A		3-COOH	< 20.0	N.T.
F8-S56	A		3-COOH	< 20.0	N.T.
F8-S57	A		3-COOH, 4-Cl	27.1	N.T.
F8-S58	A		3-COOH	33.8	N.T.
F8-S59	A		3-COOH	28.5	N.T.
F8-S60	A		4-COOH	< 20.0	N.T.
F8-S61	A		3-COOH	30.3	N.T.
F8-S62	A		3-COOH	< 20.0	N.T.
F8-S63	A		3-COOH, 4-Cl	53.4	N.T.
F8-S64	A		3-COOH	24.2	N.T.

F8-S65	A		3-NO ₂	28.8	N.T.
F8-S66	B		NO ₂	< 20.0	N.T.
F8-S67	B		NO ₂	< 20.0	N.T.
F8-S68	B		NO ₂	< 20.0	N.T.
F8-S69	B		NO ₂	< 20.0	N.T.
F8-S70	B		NO ₂	< 20.0	N.T.

^a Data are presented as geometric mean values of at least two independent runs. ^b Not tested.


Table S2. Enzymatic activity and chemical structures of the 22 analogs of **F8-S43**.

Compounds	R ¹	R ²	Inhibition% (50 μM) ^a	IC ₅₀ ± SD (μM) ^a
Tideglusib	-----	-----	98.6	0.30 ± 0.02
F8-S43	H		95.0	10.76 ± 0.48
F8-S43-S11	H	H	< 20.0	N.T. ^b
F8-S43-S12	H		< 20.0	N.T.
F8-S43-S13	H		< 20.0	N.T.
F8-S43-S14	Me		< 20.0	N.T.
F8-S43-S15	H		< 20.0	N.T.
F8-S43-S16	H		< 20.0	N.T.
F8-S43-S17	H		< 20.0	N.T.
F8-S43-S18	H		< 20.0	N.T.
F8-S43-S19	H		< 20.0	N.T.
F8-S43-S20	H		< 20.0	N.T.
F8-S43-S21	H		< 20.0	N.T.
F8-S43-S22	H		< 20.0	N.T.
F8-S43-S23	H		< 20.0	N.T.
F8-S43-S24	H		< 20.0	N.T.


F8-S43-S25	H		< 20.0	N.T.
F8-S43-S26	H		< 20.0	N.T.
F8-S43-S27	H		< 20.0	N.T.
F8-S43-S28	H		< 20.0	N.T.
F8-S43-S29	H		< 20.0	N.T.
F8-S43-S30	H		< 20.0	N.T.
F8-S43-S31	H		< 20.0	N.T.
F8-S43-S32	H		21.2	N.T.

^a Data are presented as geometric mean values of at least two independent runs. ^b Not tested.

NMR Spectra



¹H NMR of compound F8-S43 (400 MHz, DMSO-*d*₆)




¹³C NMR of compound F8-S43 (100 MHz, DMSO-*d*₆)


XEVO-G2QTOF#NotSet
dxid-4-4A_POS 13 (0.237) Cm (11:16-(2:8+27:51))

27-Jul-2020


Waters
TOF MS ES+
1.73e7




HRMS of compound **F8-S43** (ESI)




^1H NMR of compound **F8-A1** (400 MHz, $\text{DMSO-}d_6$)




¹³C NMR of compound **F8-A1** (100 MHz, DMSO-*d*₆)








¹H NMR of compound **F8-A2** (400 MHz, DMSO-*d*₆)




¹³C NMR of compound **F8-A2** (100 MHz, DMSO-*d*₆)







¹³C NMR of compound **F8-A3** (100 MHz, DMSO-*d*₆)





HRMS of compound **F8-A3** (ESI)




¹H NMR of compound **F8-A4** (400 MHz, DMSO-*d*₆)




¹³C NMR of compound **F8-A4** (100 MHz, DMSO-*d*₆)







¹³C NMR of compound **F8-A5** (100 MHz, DMSO-*d*₆)





HRMS of compound **F8-A5** (ESI)




¹H NMR of compound **F8-A6** (400 MHz, DMSO-*d*₆)




¹³C NMR of compound **F8-A6** (100 MHz, DMSO-*d*₆)








¹³C NMR of compound **F8-A7** (100 MHz, DMSO-*d*₆)




¹⁹F NMR of compound **F8-A7** (376 MHz, DMSO-*d*₆)








¹³C NMR of compound **F8-A8** (400 MHz, DMSO-*d*₆)




¹⁹F NMR of compound **F8-A8** (376 MHz, DMSO-*d*₆)







^{13}C NMR of compound **F8-A9** (100 MHz, DMSO- d_6)





HRMS of compound **F8-A9** (ESI)






¹H NMR of compound **F8-B1** (400 MHz, DMSO-*d*₆)




¹³C NMR of compound **F8-B1** (100 MHz, DMSO-*d*₆)









¹H NMR of compound **F8-B3** (400 MHz, DMSO-*d*₆)





¹H NMR of compound **F8-B4** (400 MHz, DMSO-*d*₆)




¹³C NMR of compound **F8-B4** ((100 MHz, DMSO-*d*₆)




¹⁹F NMR of compound **F8-B4** (376 MHz, DMSO-*d*₆)







¹³C NMR of compound **F8-B5** ((100 MHz, DMSO-*d*₆)





HRMS of compound **F8-B5** (ESI)




¹H NMR of compound **F8-B6** (400 MHz, DMSO-*d*₆)




¹³C NMR of compound **F8-B6** ((100 MHz, DMSO-*d*₆)







¹³C NMR of compound **F8-B7** ((100 MHz, DMSO-*d*₆)





HRMS of compound **F8-B7** (ESI)




¹H NMR of compound **F8-B8** (400 MHz, DMSO-*d*₆)




¹³C NMR of compound **F8-B8** ((100 MHz, DMSO-*d*₆)







^{13}C NMR of compound **F8-B9** ((100 MHz, DMSO- d_6))



HRMS of compound **F8-B9** (ESI)



¹H NMR of compound **F8-B10** (400 MHz, DMSO-*d*₆)






¹³C NMR of compound **F8-B10** ((100 MHz, DMSO-*d*₆)

NEGXEVO-G2QTOF#NotSet
xgf-1-110 12 (0.220) Cm (10:17-(2:7+24:36))


23-Dec-2021

Waters
TOF MS ES-
4.64e5







¹³C NMR of compound **F8-B11** (100 MHz, DMSO-*d*₆)



HRMS of compound **F8-B11** (ESI)



¹H NMR of compound **F8-B12** (400 MHz, DMSO-*d*₆)






¹³C NMR of compound **F8-B12** (100 MHz, DMSO-*d*₆)

NEGXEVO-G2QTOF#NotSet
xgf-3-37 12 (0.220) Cm (11:16-(3:8+30:41))


29-Dec-2021

Waters
TOF MS ES-
2.23e6







¹³C NMR of compound **F8-B13** (100 MHz, DMSO-*d*₆)



HRMS of compound **F8-B13** (ESI)



¹H NMR of compound **F8-B14** (400 MHz, DMSO-*d*₆)






¹³C NMR of compound **F8-B14** ((100 MHz, DMSO-*d*₆)

XEVO-G2TOF#NotSet
xgf-3-49 13 (0.237) Cm (10:16-(4:8+33:54))


22-Dec-2021

Waters
TOF MS ES+
7.06e5







¹³C NMR of compound **F8-B15** (100 MHz, DMSO-*d*₆)





HRMS of compound **F8-B15** (ESI)




¹H NMR of compound **F8-B16** (400 MHz, DMSO-*d*₆)




¹³C NMR of compound **F8-B16** (100 MHz, DMSO-*d*₆)





¹³C NMR of compound **F8-B17** ((100 MHz, DMSO-*d*₆)






¹⁹F NMR of compound **F8-B17** (376 MHz, DMSO-*d*₆)

NEGXEVO-G2QTOF#NotSet
zcf-1-19 12 (0.220) Cm (11:14-(3:8+31:38))


23-Dec-2021

Waters
TOF MS ES-
5.33e5







^{13}C NMR of compound **F8-B18** (100 MHz, $\text{DMSO-}d_6$)



HRMS of compound **F8-B18** (ESI)



¹H NMR of compound **F8-B19** (400 MHz, DMSO-*d*₆)






¹³C NMR of compound **F8-B19** ((100 MHz, DMSO-*d*₆)

NEGXEVO-G2QTOF#NotSet
xgf-1-122 11 (0.203) Cm (11:15-(4:6+34:39))


23-Dec-2021


Waters
TOF MS ES-
1.68e5






^{13}C NMR of compound **F8-B20** (100 MHz, $\text{DMSO-}d_6$)





¹H NMR of compound **F8-B21** (400 MHz, DMSO-*d*₆)





¹³C NMR of compound **F8-B21** ((100 MHz, DMSO-*d*₆)


XEVO-G2TOF#NotSet
zcf-1-20 10 (0.186) Cm (10:18-(2:7+34:58))

22-Dec-2021


Waters
TOF MS ES-
2.24e5




^1H NMR of compound **F8-B22** (400 MHz, $\text{DMSO-}d_6$)




^{13}C NMR of compound **F8-B22** (100 MHz, $\text{DMSO-}d_6$)



HRMS of compound **F8-B22** (ESI)



¹H NMR of compound **F8-C1** (400 MHz, DMSO-*d*₆)






¹³C NMR of compound **F8-C1** (100 MHz, DMSO-*d*₆)

NEGXEVO-G2QTOF#NotSet
xgf-3-36 11 (0.203) Cm (11:13-(5:11+29:49))


23-Dec-2021

Waters
TOF MS ES-
1.93e5







^{13}C NMR of compound **F8-C2** (100 MHz, DMSO- d_6)





HRMS of compound **F8-C2** (ESI)




¹H NMR of compound **F8-C3** (400 MHz, DMSO-*d*₆)




¹³C NMR of compound **F8-C3** (100 MHz, DMSO-*d*₆)





¹³C NMR of compound **F8-C4** (100 MHz, DMSO-*d*₆)



HRMS of compound **F8-C4** (ESI)